Benazeprilum [Latin] en es it fr

Benazeprilum [Latin] Brand names, Benazeprilum [Latin] Analogs

Benazeprilum [Latin] Brand Names Mixture

  • Lotensin HCT (Benazepril Hydrochloride + Hydrochlorothiazide)
  • Lotrel (Benazepril Hydrochloride + Amlodipine Besylate)

Benazeprilum [Latin] Chemical_Formula


Benazeprilum [Latin] RX_link

Benazeprilum [Latin] fda sheet

Benazeprilum_[Latin] FDA

Benazeprilum [Latin] msds (material safety sheet)

Benazeprilum_[Latin] MSDS

Benazeprilum [Latin] Synthesis Reference


Benazeprilum [Latin] Molecular Weight

424.49 g/mol

Benazeprilum [Latin] Melting Point

148-149 oC

Benazeprilum [Latin] H2O Solubility

2.229 mg/L

Benazeprilum [Latin] State


Benazeprilum [Latin] LogP


Benazeprilum [Latin] Dosage Forms

Tablet (5 mg, 10 mg, 20 mg, 40 mg)

Benazeprilum [Latin] Indication

For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

Benazeprilum [Latin] Pharmacology

Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.

Benazeprilum [Latin] Absorption

Peak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.

Benazeprilum [Latin] side effects and Toxicity

Symptoms of overdose include swelling of face, mouth, hands, or feet, trouble in swallowing or breathing (sudden), hoarseness, fever and chills.

Benazeprilum [Latin] Patient Information


Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.


Angioedema, including laryngeal edema, can occur at any time with treatment with ACE inhibitors. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

Symptomatic Hypotension

Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported to the prescribing physician. Patients should be told that if syncope occurs, Lotensin should be discontinued until the prescribing physician has been consulted.

All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.


Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.


Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

Benazeprilum [Latin] Organisms Affected

Humans and other mammals